Centessa Pharmaceuticals (CNTA)
(Delayed Data from NSDQ)
$17.02 USD
-0.16 (-0.93%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $17.00 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CNTA 17.02 -0.16(-0.93%)
Will CNTA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CNTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTA
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet
CNTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CNTA
Centessa Pharmaceuticals (CNTA) Maintains Buy Rating and $30 PT | CNTA Stock News
Alkermes narcolepsy trial results 'encouraging' for Centessa, says Leerink
Centessa Pharmaceuticals (CNTA) Gains Coverage with a 'Buy' Rating | CNTA Stock News
Truist Initiates Coverage on Centessa (CNTA) with Promising Outlook | CNTA Stock News
Centessa initiated with bullish view at Truist, here's why